BM8:F BioMarin Pharmaceutical Inc

EUR 85.32 -0.52 -0.605778
Icon

BioMarin Pharmaceutical Inc (BM8:F) Stock Analysis and Price Targets

COMMON STOCK | Biotechnology | F
stockTargetAdvisor

N/A

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Slightly Bullish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

EUR 85.32

-0.52 (-0.61)%

EUR 15.41B

1.00

N/A

N/A

Icon

BM8:F

BioMarin Pharmaceutical Inc (EUR)
COMMON STOCK | F
EUR 85.32
0.00 0
Take a Tour
stockTargetAdvisor

N/A

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Slightly Bullish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

EUR 15.41B

N/A

EUR 85.32

BioMarin Pharmaceutical Inc (BM8:F) Stock Forecast

N/A

Based on the BioMarin Pharmaceutical Inc stock forecast from 0 analysts, the average analyst target price for BioMarin Pharmaceutical Inc is not available over the next 12 months. BioMarin Pharmaceutical Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of BioMarin Pharmaceutical Inc is Slightly Bullish , which is based on 8 positive signals and 5 negative signals. At the last closing, BioMarin Pharmaceutical Inc’s stock price was EUR 85.32. BioMarin Pharmaceutical Inc’s stock price has changed by +4.33% over the past week, +10.52% over the past month and -5.14% over the last year.

No recent analyst target price found for BioMarin Pharmaceutical Inc
No recent average analyst rating found for BioMarin Pharmaceutical Inc

Company Overview BioMarin Pharmaceutical Inc

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A,...Read More

https://www.biomarin.com

770 Lindaro Street, San Rafael, CA, United States, 94901

3,401

December

EUR

Germany

Adjusted Closing Price for BioMarin Pharmaceutical Inc (BM8:F)

Loading...

Unadjusted Closing Price for BioMarin Pharmaceutical Inc (BM8:F)

Loading...

Share Trading Volume for BioMarin Pharmaceutical Inc Shares

Loading...

Compare Performance of BioMarin Pharmaceutical Inc Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for BM8:F

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To BioMarin Pharmaceutical Inc (Sector: Biotechnology )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NOVA:F
Novo Nordisk A/S +0.50 (+0.43%) EUR525.74B 45.80 4.49

ETFs Containing BM8

Symbol Name BM8's Weight Expense Ratio Price(Change) Market Cap
no data

Frequently Asked Questions About BioMarin Pharmaceutical Inc (BM8:F) Stock

Stock Target Advisor's fundamental analysis for BioMarin Pharmaceutical Inc's stock is Slightly Bullish .

Unfortunately we do not have enough data on BM8:F's stock to indicate if its a good dividend stock.

Unfortunately we do not have enough data on BM8:F's stock to indicate what its average analyst target is.

BM8:F stock's Price/Earning ratio is 100.81. Our analysis grades BM8:F stock's Price / Earning ratio at F. This means that BM8:F stock's Price/Earning ratio is above 90% of the stocks in the Biotechnology sector in the F exchange. Based on this BM8:F may be a overvalued for its sector.

The last closing price of BM8:F's stock was EUR 85.32.

The most recent market capitalization for BM8:F is EUR 15.41B.

Unfortunately we do not have enough analyst data on BM8:F's stock to indicate whether its price will go up or not.

We can't find any ETFs which contains BioMarin Pharmaceutical Inc's stock.

As per our most recent records BioMarin Pharmaceutical Inc has 3,401 Employees.

BioMarin Pharmaceutical Inc's registered address is 770 Lindaro Street, San Rafael, CA, United States, 94901. You can get more information about it from BioMarin Pharmaceutical Inc's website at https://www.biomarin.com.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...